Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer

Venus Remedies expands reach with the launch of Elores in Ecuador

The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries

Sun Pharma gets USFDA filing acceptance of new drug application for Deuruxolitinib

The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials

Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America

Emmes acquires VaxTRIALS

VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth

Cambrex completes US$38 million capacity expansion in High Point, North Carolina

Global Digital Health Summit outlines roadmap for making India a global leader in digital health implementation

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials

LEO Pharma to acquire Timber Pharmaceuticals

The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million

Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from 4 more countries

The company has secured 506 marketing approvals for its oncology products across 76 countries.